Literature DB >> 10475364

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL.

B Djavan1, A Zlotta, C Kratzik, M Remzi, C Seitz, C C Schulman, M Marberger.   

Abstract

OBJECTIVES: To enhance the specificity of prostate cancer (PCa) detection and reduce unnecessary biopsies in men with prostate-specific antigen (PSA) levels of 2.5 to 4.0 ng/mL, we prospectively evaluated various PSA-based diagnostic parameters.
METHODS: This study included 273 consecutive men with serum PSA of 2.5 to 4.0 ng/mL referred for early PCa detection or lower urinary tract symptoms. All men underwent prostate ultrasound and sextant biopsy with two additional transition zone (TZ) biopsies. If the first biopsies were negative, repeated biopsies were performed at 6 weeks. Total PSA, PSA density (PSAD), PSA density of the transition zone (PSA-TZ), free/total PSA ratio (f/t PSA), and PSA velocity (PSAV) were determined, and the sensitivity, specificity, and predictive values of these various parameters were calculated.
RESULTS: Of 273 patients, 207 had histologically confirmed benign prostatic hyperplasia (BPH) and 66 had PCa. f/t PSA and PSA-TZ were the most powerful predictors of PCa, followed by PSA, PSAD, and PSAV. Areas under the receiver operating characteristic curves for f/t PSA and PSA-TZ were 74.9% and 70.1%, respectively. With a 95% sensitivity for PCa detection, an f/t PSA cutoff of 41% and a PSA-TZ cutoff of 0.095 would result in the lowest number of unnecessary biopsies (29.3% and 17.2% specificity for f/t PSA and PSA-TZ, respectively) compared with all other PSA-related parameters evaluated.
CONCLUSIONS: Compared with standard total PSA assays, f/t PSA and PSA-TZ significantly enhance the sensitivity and specificity of PCa detection in a referral patient population with a total PSA of 2.5 to 4.0 ng/mL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475364     DOI: 10.1016/s0090-4295(99)00153-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  24 in total

1.  Prostate-specific antigen testing. Should we recommend it?

Authors:  John Hickey
Journal:  Can Fam Physician       Date:  2003-03       Impact factor: 3.275

Review 2.  The role of prostate specific antigen in screening and management of clinically localized prostate cancer.

Authors:  Khurshid Guru; Ashutosh Tewari; Ashok K Hemal; John Wei; Javid Javidan; James Peabody; Mani Menon
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

3.  [Establishing a protein signature from prostate tissue biopsies].

Authors:  U Zimmermann; R Ummanni; H Junker; S Venz; S Teller; J Giebel; R Walther
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  Office evaluation of male patients with lower urinary tract symptoms.

Authors:  Shahin Tabatabaei; Saman Shafaat Talab; Mahdi Zangi; Henry H Woo
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

Review 5.  Contrast specific imaging in the detection and localization of prostate cancer.

Authors:  Hessel Wijkstra; Margot H Wink; Jean J M C H de la Rosette
Journal:  World J Urol       Date:  2004-10-05       Impact factor: 4.226

6.  Methodology and applications of disease biomarker identification in human serum.

Authors:  Ziad J Sahab; Suzan M Semaan; Qing-Xiang Amy Sang
Journal:  Biomark Insights       Date:  2007-02-14

Review 7.  Biomarkers in prostate cancer surveillance and screening: past, present, and future.

Authors:  K Clint Cary; Mathew R Cooperberg
Journal:  Ther Adv Urol       Date:  2013-12

8.  Clinical evaluation of transrectal power doppler imaging in the detection of prostate cancer.

Authors:  Masahiko Inahara; Hiroyoshi Suzuki; Hiroshi Nakamachi; Naoto Kamiya; Masaki Shimbo; Akira Komiya; Takeshi Ueda; Tomohiko Ichikawa; Koichiro Akakura; Haruo Ito
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 9.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

Authors:  Andrew J Vickers; Caroline Savage; M Frank O'Brien; Hans Lilja
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

10.  Preliminary study on ultrasound-guided prostate biopsy specimen scores.

Authors:  Cheng Li; Weiwei Zhan; Minguang Zhang; Fangxiu Luo; Yan Wang; Bin Zheng
Journal:  Exp Ther Med       Date:  2017-07-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.